Becton Dickinson & Co Stock Price, News & Analysis

BD (NYSE: BDX) reported strong Q1 fiscal 2025 results, with revenue reaching $5.2 billion, representing a 9.8% increase as reported, 9.6% currency-neutral, and 3.9% organic growth. The company demonstrated robust financial performance with GAAP diluted EPS of $1.04 (up 8.3%) and adjusted diluted EPS of $3.43 (up 28.0%).

The company has completed $750 million in share repurchases to date in FY25 and has increased its FY25 adjusted diluted EPS guidance at the midpoint while absorbing translational currency impacts. BD also announced plans to separate its Biosciences and Diagnostic Solutions businesses to enhance value creation and focus on market-specific growth strategies.

BD (NYSE: BDX) has announced several key financial decisions. The Board declared a quarterly dividend of $1.04 per common share, payable on March 31, 2025, to shareholders of record on March 10, 2025, indicating an annual dividend rate of $4.16 per share.

The company has already completed $750 million in stock repurchases in fiscal 2025. Additionally, the Board authorized the repurchase of up to 10 million additional shares of BD common stock, supplementing the remaining shares available under the 2021 authorization. The company maintains flexibility in executing these repurchases through various methods, with timing and volume determined by management based on market conditions and business factors.

BD (NYSE: BDX) and Biosero announced a collaboration agreement to integrate robotic arms with BD flow cytometry instruments, aiming to accelerate drug discovery and development. The partnership will develop new software capabilities making BD flow cytometer instruments compatible with Biosero's Green Button Go® software.

The collaboration addresses the current manual processes in flow cytometry workflows, enabling automation of sample loading and analysis. Instead of manually changing multiwell plates one at a time, robotic integration will allow automatic processing of potentially hundreds of plates without human intervention.

The new software versions will be available for research use in 2025 for the BD FACSymphony A1™ Cell Analyzer, BD FACSymphony™ A5 SE Cell Analyzer, and BD FACSLyric™ Flow Cytometry System, with future integration planned for the BD FACSDiscover™ family of instruments.

BD (NYSE: BDX) and Biosero announced a collaboration to integrate robotic automation with BD flow cytometry instruments, aiming to accelerate drug discovery and development processes. The partnership will develop new software capabilities making BD flow cytometer instruments compatible with Biosero's Green Button Go® software.

The integration will automate manual processes in flow cytometry workflows, enabling automatic handling of multiple multiwell plates without human intervention. This automation advancement is particularly significant for biopharma companies and research organizations conducting high-throughput drug screening and cell therapy manufacturing.

The compatible software versions for BD FACSymphony A1, FACSymphony A5 SE, and FACSLyric Flow Cytometry System will be available for research use in 2025. Future integration is planned for the BD FACSDiscover family of instruments.

Carilion Clinic, serving over 1 million people in Virginia, has partnered with BD (NYSE: BDX) to become the first health system in Virginia and the Southeastern U.S. to implement needle-free blood draws using the BD® PIVO™ Pro Blood Collection Device.

The technology allows clinicians to draw blood through existing peripheral IV catheter lines, reducing multiple needlesticks, pain, and anxiety for patients. According to a Harris Poll, 51% of Americans report some fear of needles, with 31% specifically fearing multiple needle insertions.

The implementation begins at Carilion Roanoke Memorial Hospital with plans to expand to other Carilion facilities throughout the year. This initiative aims to improve patient care quality, reduce needlestick injuries, and streamline clinical workflows while minimizing complications that could lead to redraws and care delays.

BD (NYSE: BDX) has announced it will host an audio webcast on February 6, 2025, at 8 a.m. ET to discuss its first quarter fiscal 2025 financial results for the period ending December 31, 2024. During the webcast, management will present the quarterly results and provide updates on company operations and strategy.

The company will release financial summary materials and a news release prior to the webcast. Investors can access the webcast through BD's investor relations website, where a replay will also be available afterward.

BD (NYSE: BDX) announced major investments in its U.S. manufacturing capabilities for critical medical devices. The company invested over $10 million in 2024 to expand production capacity, adding new needle and syringe lines in Connecticut and Nebraska facilities. This expansion will increase domestic production of safety-engineered injection devices by >40% and conventional syringes by >50%, adding hundreds of millions of units annually.

The company hired 215 full-time employees to support increased production. Additionally, BD plans to invest over $30 million in 2025 to expand IV line manufacturing capacity at its Utah plant, following a $2 million investment in 2024 that increased IV catheter output by >40 million units annually.

BD operates more than 30 manufacturing and distribution facilities across 17 U.S. states and Puerto Rico, employing over 10,000 people. Key facilities include Nebraska (opened 1949), Connecticut (1961), and Utah (1956), which collectively represent 200 years of manufacturing experience.

BD (NYSE: BDX) announced the inclusion of its BD Onclarity™ HPV Assay in the ASCCP Enduring Risk-Based Management Guidelines, marking a significant advancement in cervical cancer screening. The assay stands out for its ability to individually identify six of the 14 cancer-causing HPV types and group the remaining seven into three pooled results, offering more precise risk assessment than traditional tests that typically identify only two types.

The new guidelines support self-collection methods for cervical cancer screening, which is available with the BD Onclarity™ HPV assay in healthcare settings. This feature aims to improve access for those facing barriers to traditional screening methods. The guidelines acknowledge that extended genotyping provides better risk stratification and that repeated detection of the same HPV type indicates higher risk of cervical pre-cancer.

BD (NYSE: BDX) has appointed Pamela Spikner as senior vice president, chief accounting officer and controller, effective January 20. Reporting to CFO Chris DelOrefice, Spikner will oversee all accounting policy and financial reporting for the company.

Spikner brings over 25 years of experience in corporate finance and accounting. She joins BD from R1 RCM, Inc., where she served as chief accounting officer since July 2021, managing financial reporting, compliance, and strategic financial planning. Her previous roles include accounting leadership positions at Exelon for 12 years and assistant corporate controller at Hill-Rom Holdings. She started her career at PwC in the audit practice focusing on healthcare and insurance industries.

A certified public accountant (CPA) and certified internal auditor (CIA), Spikner holds a Bachelor of Science in Accounting from Indiana University of Pennsylvania.